Our latest articles
Could Gilead soon be looking for a new partner for its long-acting project lenacapavir?
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
The usually conservative group spends big on Dicerna – but others might be interested too.